Searched for
MANKIND PHARMA REVENUE GROWTH
Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...- Largecaps lead profit growth, mid & smallcaps outshine in revenue momentum in Q4Large companies saw stronger net profit growth for the March 2026 quarter, driven by one-off gains, despite slower revenue expansion and wi...
- Stocks in news: Vedanta, Honasa Consumer, IRCTC, Bajaj Auto, Tata MotorsIndian markets experienced profit booking, falling over a percent amidst a weak global trend. Key stocks like Vedanta, Honasa Consumer, IRC...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Big Four firms' India operations shine amid global slumpIndia's Big Four accounting firms have achieved remarkable growth, outperforming global peers in fiscal year 2026. PwC and Deloitte reporte...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- West Asia conflict may pressure hospitality occupancy, warns ICRA; FY27 estimate at 72-74%Hospitality sector occupancy is projected at 66-68% for early FY27, rising to 72-74% for the full year, according to ICRA. However, prolong...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Hotel chains unfazed despite geopolitical shocks, high fuel costsHotel chains in India are reporting double-digit revenue growth in the April–June quarter despite geopolitical tensions, higher fuel costs ...
- Growth over scale: NSE is priced at a discount to BSENSE's upcoming IPO is set for a discount compared to its peer BSE. This valuation reflects slower growth in NSE's core business. BSE, howev...
- Accenture cuts revenue outlook, stock crashes 17%Accenture has lowered its annual revenue growth forecast. Companies are still cautious about spending on technology. This is happening even...
- Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...
- Indian pharma market's double-digit growth momentum is likely to continue further: EquirusThe Indian Pharmaceutical Market is set for continued double-digit growth. May's performance showed strong demand across all therapies. Chr...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
Load More
